Press releases and news
2024
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023
2023
Change in number of shares and votes in Camurus
Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly
Camurus to enter Large Cap segment on Nasdaq Stockholm
Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors
Camurus’ Interim Report Third Quarter 2023
Camurus receives improved ESG risk rating by Sustainalytics
Camurus to present at Jefferies 2023 Healthcare Conference London
Camurus raises financial guidance for the full year 2023
Camurus’ Nomination Committee appointed for the Annual General Meeting 2024
Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund
Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn
Change in number of shares and votes in Camurus
Exercise of Camurus’ subscription warrant program 2020/2023
Camurus’ Interim Report Second Quarter 2023
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial
Camurus accepted as participant of the United Nations Global Compact
Change in number of shares and votes in Camurus
Camurus to present at Jefferies 2023 Healthcare Conference New York
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.